Trials / Unknown
UnknownNCT04880811
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
Phase 2 Study of Afatinib Plus Toripalimab in Previously Treated Recurrent or Metastasic Esophageal Squamous Cell Carcinoma With EGFR Overexpression or EGFR Amplification
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 trial investigating the effect and safety of afatinib plus toripalimab in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afatinib | Afatinib is orally administered at 40mg Qd of each 21 day cycle. |
| DRUG | Toripalimab | Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle. |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2022-10-01
- Completion
- 2023-05-01
- First posted
- 2021-05-11
- Last updated
- 2021-07-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04880811. Inclusion in this directory is not an endorsement.